List of Excipients in Branded Drug XALKORI

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pfizer Laboratories Div Pfizer Inc	XALKORI	crizotinib	0069-8140	AMMONIA	2029-10-08
Pfizer Laboratories Div Pfizer Inc	XALKORI	crizotinib	0069-8140	ANHYDROUS DIBASIC CALCIUM PHOSPHATE	2029-10-08
Pfizer Laboratories Div Pfizer Inc	XALKORI	crizotinib	0069-8140	CELLULOSE, MICROCRYSTALLINE	2029-10-08
Pfizer Laboratories Div Pfizer Inc	XALKORI	crizotinib	0069-8140	FERRIC OXIDE RED	2029-10-08

Xalkori Excipient Strategy and Commercial Opportunities for Crizotinib

Last updated: August 9, 2026

Xalkori contains crizotinib, a small-molecule ALK and ROS1 tyrosine kinase inhibitor marketed by Pfizer. Its formulation is commercially conventional: immediate-release hard capsules and oral pellets using standard excipients such as lactose, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, and colloidal silicon dioxide. The strongest commercial opportunities are therefore not basic excipient substitution. They are in pediatric delivery, capsule-to-pellet conversion, low-cost generic manufacturing, taste masking, dose flexibility, and differentiated formulations that support a 505(b)(2) or lifecycle strategy.[1]

What excipients are used in Xalkori capsules and oral pellets?

Xalkori is supplied as 200 mg and 250 mg hard capsules and as oral pellets in 20 mg, 50 mg, and 150 mg strengths. The oral-pellet presentation is important because it expands administration options for patients who cannot reliably swallow capsules.[1]

Xalkori capsule excipients

The Xalkori capsule formulation uses:

Formulation component	Reported function
Crizotinib	Active pharmaceutical ingredient
Microcrystalline cellulose	Diluent and compression or fill aid
Anhydrous lactose	Diluent
Sodium starch glycolate	Superdisintegrant
Colloidal silicon dioxide	Glidant and flow aid
Magnesium stearate	Lubricant
Gelatin capsule shell	Dosage-form shell
Titanium dioxide and iron oxide colorants	Capsule identification and appearance

The formulation is designed for immediate release rather than modified release. The excipient system prioritizes powder flow, capsule-fill uniformity, rapid disintegration, and scalable manufacturing.[1]

Xalkori oral-pellet excipients

The oral-pellet product uses a multiparticulate approach. The pellet platform can improve dose flexibility and administration in pediatric patients, while preserving oral immediate-release delivery. Its commercial value is linked to:

• controlled pellet size distribution;
• reproducible crizotinib loading;
• acceptable mouthfeel;
• reduced segregation during filling;
• protection against moisture and abrasion;
• compatibility with soft foods or liquids, where permitted by labeling;
• accurate administration of low pediatric doses.

The exact manufacturing process and excipient grades are more commercially sensitive than the broad qualitative composition disclosed in the prescribing information. A generic applicant must establish pharmaceutical equivalence and demonstrate comparable dissolution and product performance under the applicable ANDA pathway.[1,2]

What excipient functions create the largest commercial opportunity?

The most attractive opportunities involve excipient performance rather than commodity supply alone.

1. Superdisintegrants and rapid drug release

Sodium starch glycolate supports rapid capsule disintegration. A generic manufacturer could evaluate crospovidone, croscarmellose sodium, or alternative grades of sodium starch glycolate. The commercial objective would be to match or improve dissolution while controlling:

• disintegration time;
• dissolution variability;
• sensitivity to lubricant concentration;
• moisture uptake;
• capsule-fill weight;
• stability during accelerated storage.

A substitution that changes dissolution or bioavailability may require additional development work. The lowest-risk approach is usually a Q1/Q2-aligned composition using excipients already accepted in the relevant oral dosage form and strength.

2. Co-processed excipients

Co-processed microcrystalline cellulose systems could combine dilution, flow, and disintegration functions. Potential benefits include lower formulation complexity and improved high-speed encapsulation. Commercial value is highest if the platform reduces:

• blend segregation;
• weight variation;
• production yield loss;
• lubricant sensitivity;
• dependence on narrow particle-size distributions.

A co-processed excipient may create a technical barrier if it delivers superior content uniformity or robust manufacturing at lower compression or filling forces. It does not, by itself, avoid drug-product patent or regulatory obligations.

3. Low-lactose and lactose-free systems

Xalkori uses lactose in the capsule formulation. A lactose-free version could use mannitol, dicalcium phosphate, spray-dried cellulose, or a co-processed filler. The opportunity is commercially relevant for patients with lactose concerns and for manufacturers seeking a differentiated label.

The principal development risks are altered powder density, flow, dissolution, and capsule size. A lactose-free product would also need careful evaluation of excipient tolerability, especially in pediatric populations.

4. Lubricant optimization

Magnesium stearate is a standard lubricant but can slow dissolution when over-lubrication occurs. A manufacturer may assess lower lubricant levels, shorter lubrication times, or alternative lubricants such as sodium stearyl fumarate. The formulation target is consistent capsule filling without creating a hydrophobic surface that delays drug release.

This is a manufacturing optimization opportunity rather than a strong standalone patent position.

What formulations could be protected around crizotinib?

A formulation patent covering the marketed Xalkori capsule composition would require a novel and non-obvious technical feature. Routine substitution of lactose, microcrystalline cellulose, or magnesium stearate would generally face a weak patentability position unless the change produces an unexpected result.

Potential formulation patent themes

Strategy	Potential claim focus	Commercial value
Pediatric multiparticulates	Crizotinib-loaded pellets with defined size, loading, and release profile	High
Taste masking	Coating, ion exchange, lipid barrier, or polymer matrix	High for pediatric use
Low-dose delivery	Accurate 20 mg or lower dose administration	High for pediatric and dose-reduction markets
Improved stability	Moisture-protected or oxidation-resistant formulation	Moderate
Enhanced dissolution	Particle-size control, amorphous dispersion, or wetting system	Moderate to high
Sprinkle administration	Pellets compatible with specified foods or liquids	High if clinically and regulatorily supported
Alternative excipients	Lactose-free or sugar-free composition	Moderate
Manufacturing process	Pelletization, coating, drying, or encapsulation parameters	Moderate

The most defensible formulation claims would connect composition to measurable performance. Examples include a defined dissolution profile, improved stability, reduced dose variability, or a demonstrated reduction in bitterness. Broad claims that simply list conventional excipients would face higher obviousness risk.

When does Xalkori lose exclusivity?

Xalkori received FDA approval on August 26, 2011, for metastatic non-small cell lung cancer with ALK rearrangement. The product later received indications involving ROS1-positive metastatic NSCLC and pediatric patients with relapsed or refractory systemic anaplastic large cell lymphoma.[1]

Milestone	Date or status
Initial FDA approval	August 26, 2011
Active ingredient	Crizotinib
Initial regulatory pathway	New molecular entity approval
NCE exclusivity	Generally five years from approval, subject to statutory exceptions
Foundational composition-of-matter patent	Publicly reported expiry in 2029, subject to patent-term adjustment and Orange Book status
Capsule and oral-pellet commercial forms	Both marketed by Pfizer
Biosimilar pathway	Not applicable; crizotinib is a small molecule
Generic pathway	ANDA, subject to reference-listed-drug and patent certifications

The practical generic-entry date depends on the live Orange Book listing, patent-term adjustment, pediatric exclusivity, regulatory exclusivity, litigation outcomes, and any settlement agreement. A 2029 patent expiry is the key public anchor for the foundational crizotinib patent estate, but commercial entry could occur earlier through a successful Paragraph IV challenge or an agreed launch date.[2,3]

What is the Orange Book status of Xalkori?

Xalkori is an FDA-approved small-molecule product and is evaluated through the Orange Book framework. The relevant Orange Book analysis should distinguish:

1. patents claiming crizotinib or its composition;
2. patents claiming formulations;
3. patents claiming approved methods of use;
4. patents with expiration dates that control ANDA certification;
5. patents listed for some strengths or dosage forms but not others.

The Orange Book does not determine every possible patent risk. It does identify patents that an ANDA applicant must address through Paragraph I, II, III, or IV certification. A generic applicant may also face non-Orange Book process, formulation, manufacturing, or foreign patent claims.

Paragraph IV challenge risks

A Paragraph IV applicant would typically target one or more of the following:

• invalidity of the foundational composition patent;
• non-infringement based on the proposed generic formulation;
• lack of patent relevance to the ANDA product;
• expiration or unenforceability of listed method-of-use patents;
• design-around of pellet or capsule claims;
• absence of infringement for indications carved out under a section viii statement.

The commercial strength of a Paragraph IV case depends on claim construction, prosecution history, prior art, patent-term calculations, and the precise proposed label. A product with only conventional excipients may have a relatively straightforward formulation non-infringement position, but the foundational active-ingredient patent remains the central barrier if it is listed and enforceable.

What patent litigation affects Xalkori generic entry?

The central litigation question is whether an ANDA applicant can obtain approval before the reported 2029 expiry of Pfizer’s foundational patent. A generic applicant that submits a Paragraph IV certification may trigger patent litigation under the Hatch-Waxman framework. Filing litigation within the statutory period can produce a 30-month stay of FDA approval, subject to statutory exceptions and court developments.[3]

Public commercial analysis should separate:

• patent litigation involving the active ingredient;
• litigation involving pediatric or pellet formulations;
• litigation over method-of-use patents;
• settlements that permit an earlier authorized-generic or independent-generic launch;
• cases dismissed after claim narrowing or label amendments.

No biosimilar litigation model applies because Xalkori is not a biologic. The relevant competitive events are ANDA filings, Paragraph IV notices, district-court litigation, Federal Circuit appeals, and potential settlement agreements.

How strong is the Xalkori patent estate?

The estate is strongest where claims cover crizotinib itself or a composition-of-matter invention. Those claims can block products regardless of whether a generic uses different excipients. Formulation and method-of-use claims are narrower and more vulnerable to design-around, label carve-outs, or invalidity challenges.

Relative strength by patent category

Patent category	Blocking potential	Design-around risk
Crizotinib composition of matter	High	Low
Specific salt or solid form	Moderate to high	Moderate
Capsule formulation	Moderate	Moderate to high
Oral pellets	Moderate	Moderate
Pediatric administration method	Moderate	High
Indication-specific method of use	Variable	High through label carve-out
Manufacturing process	Variable	Moderate to high

The commercial importance of pellet claims is greater than their patent breadth may suggest. A competitor may avoid a pellet patent by launching capsules, but pediatric treatment demand and dose flexibility can make the pellet presentation strategically important.

What generic entry scenarios exist for Xalkori?

Scenario 1: Patent expiry launch

The lowest-risk path is approval timed to patent expiry or an agreed settlement date. This approach reduces litigation cost but delays market entry and compresses the opportunity for early share capture.

Scenario 2: Paragraph IV launch

An ANDA applicant may challenge the foundational patent and seek approval before expiry. Success would depend on invalidity or non-infringement. The reward is earlier entry into a market with established clinical use, but the applicant faces litigation costs and potential damages exposure.

Scenario 3: Capsule-only entry

A generic company could launch capsules while omitting or delaying oral pellets. This reduces formulation complexity and avoids some pediatric product-development costs. The product would compete primarily on price and supply reliability.

Scenario 4: Differentiated pediatric entry

A manufacturer could pursue oral pellets, taste masking, lower-dose administration, or a 505(b)(2) product. The opportunity is smaller than the adult capsule market but may support stronger pricing and physician differentiation.

Scenario 5: Authorized-generic competition

Pfizer or a commercial partner could introduce an authorized generic around or before independent generic entry. That would reduce the price premium available to first independent entrants and could strengthen Pfizer’s control over supply-chain economics.

What excipient suppliers can sell into the Xalkori market?

The largest opportunity is not a proprietary excipient dedicated to Xalkori. It is a formulation and manufacturing package built around regulatory-ready excipient grades.

Attractive supplier offerings

• directly compressible or capsule-compatible microcrystalline cellulose;
• low-moisture anhydrous lactose;
• high-performance sodium starch glycolate;
• low-peroxide colloidal silicon dioxide;
• low-level lubricant systems;
• co-processed fillers with improved flow;
• pelletization binders;
• taste-masking polymers;
• moisture-barrier coating systems;
• excipients with strong global regulatory documentation.

Suppliers can increase switching costs by providing formulation support, analytical data, impurity control, and region-specific regulatory files. Generic manufacturers will value consistent particle-size distribution, low microbial burden, reliable supply, and documented compliance with FDA, European Union, and other major-market requirements.

How does Xalkori compare with competing ALK inhibitors?

Xalkori competes with newer ALK inhibitors including alectinib, brigatinib, lorlatinib, and ceritinib. Those products have different clinical positioning, CNS activity, dosing schedules, and patent timelines. Xalkori’s commercial vulnerability is greatest where physicians prefer newer agents for central nervous system control or first-line durability.

That competitive pressure creates two formulation opportunities:

1. lower-cost supply for price-sensitive markets after generic entry;
2. pediatric and administration-friendly products where newer competitors do not offer equivalent dosage flexibility.

The small-molecule status of all these products means the competitive landscape is driven by traditional generic entry, formulation differentiation, and patent timing rather than biosimilar substitution.

What is the revenue exposure from Xalkori patent expiry?

Pfizer does not consistently disclose Xalkori as a separately reported major revenue line in its principal financial reporting. Its commercial exposure is therefore best assessed through product-level sales disclosures, prescription volume, indication mix, and the timing of generic entry rather than through a standalone segment figure.[4]

Revenue erosion would likely be gradual if generic entry begins with capsules and later expands to pellets. Price erosion could be faster in markets with multiple ANDA approvals. Pediatric formulations may retain a premium if they offer administration advantages that standard capsules do not provide.

Key Takeaways

• Xalkori uses a conventional immediate-release excipient system centered on lactose, microcrystalline cellulose, sodium starch glycolate, colloidal silicon dioxide, and magnesium stearate.
• The strongest commercial opportunity is oral-pellet and pediatric delivery, not routine excipient substitution.
• Crizotinib is a small molecule, so biosimilar risk is irrelevant. Generic ANDA and Paragraph IV risk are the governing competitive mechanisms.
• The foundational crizotinib patent is publicly associated with an expiry in 2029, subject to the live Orange Book record and patent-term calculations.
• Capsule-only generic entry is simpler and likely to precede or outpace differentiated pellet competition.
• Formulation patents are most defensible when tied to measurable improvements in dissolution, stability, taste, dose accuracy, or pediatric administration.
• Pfizer’s product-level revenue exposure is not consistently isolated in public financial reporting, making generic-entry timing more important than a headline sales estimate.

FAQs

Can a generic Xalkori use different excipients?

Yes. An ANDA applicant can use different excipients if the product meets pharmaceutical-equivalence, bioequivalence, quality, stability, and labeling requirements. The applicant must also address applicable listed patents.

Is Xalkori oral-pellet technology more valuable than the capsule formulation?

Potentially. Pellets support pediatric dosing and may create differentiation through taste masking, dose flexibility, and administration convenience. Their value depends on clinical demand and whether patent claims can be designed around.

Can a lactose-free crizotinib formulation obtain separate market exclusivity?

A lactose-free composition may support patent protection only if it satisfies novelty and non-obviousness requirements. It does not automatically receive regulatory exclusivity.

Are crizotinib excipients subject to FDA approval as separate products?

Excipients are not generally approved through the same pathway as active pharmaceutical ingredients. Their acceptability depends on prior use, safety, dosage form, route, concentration, and FDA regulatory review.

Which manufacturing barrier is most important for crizotinib pellets?

Uniform drug loading and reproducible pellet size are central barriers. Taste masking, coating integrity, moisture control, and accurate low-dose filling also affect commercial scalability.

References

1. U.S. Food and Drug Administration. (2024). Xalkori (crizotinib) prescribing information. Pfizer Laboratories.
2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Code, 21 U.S.C. § 355(j). Abbreviated new drug applications and patent certifications.
4. Pfizer Inc. (2024). Annual report and Form 10-K.